EMERGE (Study 302)
E133123
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
All labels observed (1)
| Label | Occurrences |
|---|---|
| EMERGE (Study 302) canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1172237 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: EMERGE (Study 302) Context triple: [Aduhelm, clinicalTrial, EMERGE (Study 302)]
-
A.
Study 301
Study 301 is a pivotal clinical trial evaluating the efficacy and safety of the Alzheimer’s disease drug Leqembi (lecanemab) in patients with early-stage disease.
-
B.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
CAPTOR-E
CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
-
E.
Jackson Heart Study
The Jackson Heart Study is a large, long-term epidemiological research project focused on understanding cardiovascular disease and its risk factors among African American communities, particularly in Jackson, Mississippi.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: EMERGE (Study 302) Target entity description: EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
A.
Study 301
Study 301 is a pivotal clinical trial evaluating the efficacy and safety of the Alzheimer’s disease drug Leqembi (lecanemab) in patients with early-stage disease.
-
B.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
CAPTOR-E
CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
-
E.
Jackson Heart Study
The Jackson Heart Study is a large, long-term epidemiological research project focused on understanding cardiovascular disease and its risk factors among African American communities, particularly in Jackson, Mississippi.
- F. None of above. chosen
Statements (37)
| Predicate | Object |
|---|---|
| instanceOf |
Phase 3 clinical trial
ⓘ
clinical trial ⓘ pivotal trial ⓘ |
| biomarkerAssessment | amyloid plaque levels in the brain ⓘ |
| coDeveloperCompany | Eisai ⓘ |
| controlType | placebo ⓘ |
| designFeature |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| diseaseCategory |
dementia
ⓘ
neurocognitive disorder ⓘ |
| drugBrandName | Aduhelm ⓘ |
| drugGenericName |
Aduhelm
ⓘ
surface form:
aducanumab
|
| drugTarget | amyloid beta ⓘ |
| drugType | monoclonal antibody ⓘ |
| evaluatesDrug |
Aduhelm
ⓘ
Aduhelm ⓘ
surface form:
aducanumab
|
| geographicScope | multinational ⓘ |
| hasPhase | Phase 3 ⓘ |
| indication |
Alzheimer's disease
ⓘ
surface form:
Alzheimer’s disease
|
| intervention | intravenous aducanumab ⓘ |
| mechanismOfAction | anti-amyloid beta monoclonal antibody ⓘ |
| patientPopulation |
patients with early Alzheimer’s disease
ⓘ
patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia ⓘ |
| primaryEndpointDomain | cognition and function in Alzheimer’s disease ⓘ |
| primaryEndpointType | clinical efficacy ⓘ |
| primaryObjective | evaluate efficacy of aducanumab in early-stage Alzheimer’s disease ⓘ |
| regulatoryRole | pivotal study supporting FDA review of aducanumab ⓘ |
| relatedTrial | ENGAGE (Study 301) ⓘ |
| safetyAssessment |
adverse events related to aducanumab
ⓘ
amyloid-related imaging abnormalities (ARIA) ⓘ |
| secondaryObjective | evaluate safety of aducanumab in early-stage Alzheimer’s disease ⓘ |
| sponsor | Biogen ⓘ |
| sponsorCountry |
United States of America
ⓘ
surface form:
United States
|
| targetsDiseaseStage | early-stage Alzheimer’s disease ⓘ |
| therapeuticArea |
neurodegenerative diseases
ⓘ
neurology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: EMERGE (Study 302) Description of subject: EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.